Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. Jan. 14, 2019. Jos Van Vroonhoven.

Executive Summary

Jos Van Vroonhoven, a senior manager for standardization for Philips Healthcare and the convener of a joint working group that is revising risk management standard ISO 14971, said the document was upgraded to strengthen benefit-risk language and make its recommendations more clear. See what he had to say here.

"When revising the standard, we wanted to keep as much of it as possible the same. So, there are no changes to the risk management process, but there is more clarification and alignment with regulatory requirements that have changed. One of those changes by regulators is more emphasis on benefit-risk." Jos Van Vroonhoven, senior manager for standardization, Philips Healthcare

Click here for a free trial of Medtech Insight

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel